October 2, 2009 – Cardiovascular magnetic resonance (CMR) in the evaluation of patients with heart failure (HF) “will expand substantially in the coming years,” according to the authors of a study published in October 2009 issue of the Journal of American College of Cardiology.

In the study, The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure, the authors emphasize the efficacy of CMR in assessing myocardial anatomy, regional and global function, and viability, and assessment of perfusion and acute tissue injury, and notes that CMR often “reveals the underlying etiology of heart failure, and its high measurement accuracy makes it an ideal technique for monitoring disease progression and the effects of treatment.” They add that increasing evidence that “the prognostic value of CMR-derived parameters in heart failure is rapidly emerging.”

“We predict that most patients with HF will eventually undergo CMR imaging as part of the diagnostic workup and to guide management and stratify risk,” the authors wrote.

The researchers listed the proposed indications for the use of CMR in HF patients that are likely to further expand in the near future. These indications include:
- Serial assessment of biventricular structure, size, and function (anatomy, LV/RV volumes, global and regional systolic function, mass)
- Evaluation of native and prosthetic cardiac valves (planimetry of stenotic disease, estimation of peak stenotic velocities and gradients, quantification of regurgitant disease)
- Evaluation of cardiac masses, differentiation between tumor and thrombus
- Evaluation of great vessels and pulmonary veins
- Determination of the location and extent of acute (including no-reflow regions) and chronic myocardial necrosis
Viability assessment before revascularization (LGE or low-dose dobutamine)
- Determination of the area at risk in patients with acute myocardial infarction and the salvageable area post-revascularization with percutaneous coronary intervention
- Identification of the presence and quantification of the extent of inducible ischemia (vasodilator perfusion or high-dose dobutamine stress CMR)
- Evaluation of suspected anomalous coronary origins (MR coronary angiography)
- Differentiation of ischemic versus nonischemic cardiomyopathy
- Evaluation of myocarditis
- Evaluation of specific cardiomyopathies (in vivo tissue characterization)
- Assessment of mechanical dyssynchrony before resynchronization therapy
- Patients with technically limited images from echocardiogram
- Discordant information that is clinically significant from prior tests

Plus, in their conclusion, the researchers anticipate that “improvement in software and hardware will further shorten scan times and allow the use of real-time imaging with better spatial and temporal resolution. New CMR techniques aiming at the identification and quantification of diffuse fibrosis will further improve the in vivo assessment of myocardial pathology.”

They pointed to other growth for CMR that include: novel CMR contrast agents, stem cell therapy monitored by CMR, interventional CMR to guide therapeutic procedures, and finally MR spectroscopy to assess metabolic changes in the failing heart and monitoring of the response to novel forms of metabolic therapy.

Reference: Theodoros D. Karamitsos, M.D., Ph.D.,* Jane M. Francis, DCC(R), DNM,* Saul Myerson, M.D.,* Joseph B. Selvanayagam, MBBS, DPHIL,† Stefan Neubauer, M.D.,* Oxford, United Kingdom; and Adelaide, Australia. The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure. J Am Coll Cardiol, 2009; 54:1407-1424, doi:10.1016/j.jacc.2009.04.094

For more information: www.ocmr.ox.ac.uk


Related Content

News | Prostate Cancer

June 26, 2025 – Quibim, a global provider of quantitative medical imaging solutions, has launched AI-QUAL, a new feature ...

Time June 26, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
News | Women's Health

Aug. 19, 2024 — GE HealthCare recently announced a collaboration with the University of California San Diego School of ...

Time August 29, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
Subscribe Now